Moderna is downsizing its workforce by 10% globally to bring headcount to under 5,000 in “a difficult moment for the company, ...

Rumors of Biogen’s disagreements with Eisai have been greatly exaggerated, CEO Chris Viehbacher said during a second quarter ...

Employed biopharma professionals are highly likely to look for new jobs in the next 12 months, although not quite as likely ...

In this episode presented by IQVIA, BioSpace’s head of insights Lori Ellis discusses the concerns and opportunities of ...

Rinvoq’s efficacy in alopecia areata is “impressive,” according to Guggenheim analysts, who said the drug could have a ...

Long-term extension data presented at the Alzheimer's Association International Conference showed amyloid plaque ...

Looking for a biopharma job in North Carolina? Check out the BioSpace list of seven companies hiring life sciences ...

While Eli Lilly’s diabetes blockbuster was non-inferior to its older incretin therapy Trulicity in a highly anticipated Phase III cardiovascular outcomes trial, analysts had hoped for statistical ...

As analysts parsed news of Vinay Prasad’s ouster, worries over drug approval delays, cell and gene therapy impacts and more ...

George Tidmarsh has only been at the Center for Drug Evaluation and Research for nine days, but will now add supervision of a ...

A new report found that 85% of pharma respondents are increasing their artificial intelligence investments, and 70% see AI as an immediate priority. Two experts discuss how biopharmas are implementing ...

Madrigal will study SYH2086 in combination with Rezdiffra for metabolic dysfunction-associated steatohepatitis, aiming for ...